Skip to main content
MedicHelpLine
Join Free
Verified Professional Network190+ CountriesHIPAA-Aware Platform
Back to Drug Index
General MedicationsORAL-28Generic

RHUZDAH

ETHINYL ESTRADIOL; NORETHINDRONE

Standard Dose
0.035MG;0.4MG
Max Dose
Refer to approved labeling
Primary Use
Review priority: STANDARD Marketing status: Discontinued
Summary

Approval overview RHUZDAH is listed in Drugs@FDA under application 207585 (ANDA).

Review priority: STANDARD Marketing status: Discontinued Active ingredient ETHINYL ESTRADIOL; NORETHINDRONE Form and strength TABLET;ORAL-28 - 0.035MG;0.4MG Sponsor AUROBINDO PHARMA Submission history Latest submission status date: 2022-10-11 00:00:00.

Structured Monograph

Clinical summary

Approval overview RHUZDAH is listed in Drugs@FDA under application 207585 (ANDA). Review priority: STANDARD Marketing status: Discontinued Active ingredient ETHINYL ESTRADIOL; NORETHINDRONE Form and strength TABLET;ORAL-28 - 0.035MG;0.4MG Sponsor AUROBINDO PHARMA Submission history Latest submission status date: 2022-10-11 00:00:00. Submission type: ORIG.

Monitoring

  • • Marketing status: Discontinued
  • • Review priority: STANDARD

Interaction Notes

  • No interaction notes stored yet.